Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 05 2019
Historique:
received: 02 03 2018
accepted: 19 11 2018
entrez: 16 5 2019
pubmed: 16 5 2019
medline: 30 10 2020
Statut: epublish

Résumé

Liver fibrosis is characterised by a dense and highly cross-linked extracellular matrix (ECM) which promotes progression of diseases such as hepatocellular carcinoma. The fibrotic microenvironment is characterised by an increased stiffness, with rigidity associated with disease progression. External stiffness is known to promote hepatic stellate cell (HSC) activation through mechanotransduction, leading to increased secretion of ECM components. HSCs are key effector cells which maintain the composition of the ECM in health and disease, not only by regulating secretion of ECM proteins such as collagen, but also ECM-degrading enzymes called matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). Uninhibited MMPs degrade ECM proteins to reduce external rigidity. Using fibronectin-coated polyacrylamide gels to alter substrate rigidity without altering ligand density, we show that fibrotic rigidities downregulate MMP-9 expression and secretion, and also upregulate secretion of TIMP-1, though not its expression. Using tissue immunofluorescence studies, we also report that the expression of MMP-9 is significantly decreased in activated HSCs in fibrotic tissues associated with hepatocellular carcinoma. This suggests the presence of a mechanical network that allows HSCs to maintain a fibrotic ECM, with external rigidity providing feedback which affects MMP-9 and TIMP-1 secretion, which may become dysregulated in fibrosis.

Identifiants

pubmed: 31086224
doi: 10.1038/s41598-019-43759-6
pii: 10.1038/s41598-019-43759-6
pmc: PMC6514003
doi:

Substances chimiques

RNA, Small Interfering 0
TIMP1 protein, human 0
Tissue Inhibitor of Metalloproteinase-1 0
MMP9 protein, human EC 3.4.24.35
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7299

Références

Nat Commun. 2013;4:2823
pubmed: 24264436
Cardiovasc Res. 2006 Feb 15;69(3):562-73
pubmed: 16405877
Hepat Med. 2010 May 25;2:49-67
pubmed: 24367208
FASEB J. 2014 Aug;28(8):3589-99
pubmed: 24784579
Liver Cancer. 2013 Aug;2(3-4):365-6
pubmed: 24400223
J Biol Chem. 2007 Dec 28;282(52):37585-96
pubmed: 17848556
J Hepatol. 2002 Feb;36(2):200-9
pubmed: 11830331
Hepatology. 2016 Jul;64(1):261-75
pubmed: 26755329
Eur Respir J. 2011 Jul;38(1):191-208
pubmed: 21177845
Nat Rev Mol Cell Biol. 2009 Jan;10(1):63-73
pubmed: 19197333
Biochim Biophys Acta. 2010 Jan;1803(1):3-19
pubmed: 19631700
Dig Dis Sci. 1993 Aug;38(8):1473-9
pubmed: 8344103
Nat Rev Mol Cell Biol. 2014 Dec;15(12):786-801
pubmed: 25415508
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
Nat Mater. 2014 Oct;13(10):979-87
pubmed: 25108614
Arch Pathol Lab Med. 2007 Nov;131(11):1728-34
pubmed: 17979495
Biochim Biophys Acta. 2013 Jul;1832(7):884-90
pubmed: 23434892
Front Pharmacol. 2016 Dec 01;7:462
pubmed: 27990121
Curr Opin Pharmacol. 2016 Aug;29:26-33
pubmed: 27262779
Ann Surg Oncol. 2012 Jul;19 Suppl 3:S375-84
pubmed: 21681378
Sci Rep. 2016 Feb 24;6:21387
pubmed: 26906177
Methods Mol Biol. 2013;935:245-54
pubmed: 23150373
Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):195-206
pubmed: 21497738
Matrix Biol. 2015 May-Jul;44-46:147-56
pubmed: 25599939
Annu Rev Pathol. 2017 Jan 24;12:153-186
pubmed: 27959632
Circulation. 2009 Apr 28;119(16):2209-16
pubmed: 19364980
Cell Struct Funct. 1999 Oct;24(5):255-61
pubmed: 15216880
Oncoimmunology. 2017 Aug 4;6(11):e1358332
pubmed: 29147618

Auteurs

Dariusz Lachowski (D)

Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Faculty of Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.

Ernesto Cortes (E)

Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Faculty of Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.

Alistair Rice (A)

Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Faculty of Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK.

David Pinato (D)

Hammersmith Hospital, Imperial College London, London, W12 0HS, UK.

Krista Rombouts (K)

Regenerative Medicine and Fibrosis Group, Institute for Liver and Digestive Health, University College London, Royal Free Hospital, London, UK.

Armando Del Rio Hernandez (A)

Cellular and Molecular Biomechanics Laboratory, Department of Bioengineering, Faculty of Engineering, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK. a.del-rio-hernandez@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH